solid end multipl product catalyst deliv
wednesday januari abbott report fourth-quart result came
expect revenu growth high singl digit adjust earn growth
manag put forth in-lin guidanc organ revenu growth
adjust ep growth midpoint view
continu recent strong trend seen compani segment
continu lead pack name medic devic specif structur heart
diabet core laboratori diagnost specif alin establish pharmaceut
overal noth caus us question thesi base revenu
growth top group earn growth doubl digit even face
difficult fx environ infrastructur invest new opportun varieti
segment import strateg flexibl reflect guidanc model
robert ford prepar take helm ceo follow mile white retir
believ vision futur mirror similar strategi current held believ
compani continu execut penetr mani larg under-penetrated
growth opportun drive consist leverag bottom line term
capit alloc highlight compani continu build cash posit
increas strateg flexibl net leverag today stand time
compani paid close billion debt last two year solid
ebitda believ move closer time time well
believ appropri busi continu wait patient
manag detail exactli plan cash manag
commentari remain dismiss near-term hear
past sever quarter though believ could chang quickli model use
suggest build-up cash modest interest made though believ
wind realiti manag team investor satisfi
stock thought head believ end-market demand remain
robust across segment margin expans play pipelin new product
launch continu gain traction back substanti invest cash
flow creat accret opportun believ support current multipl
time ep compar three-year averag time room
upsid result number lever compani avail rate abbott
abbott highli diversifi provid medic devic nutrit pharmaceut product
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
return equiti ttm
risk risk thesi includ lower-than-expect sale caus competit compani key market
lower reimburs rate product respect procedur slower-than-anticip adopt util
product among physician and/or patient bottom line abbott ep growth depend oper effici
could materi off-set invest within compani grow product line global compani
abbott exposur sever intern countri introduc oper fx risk
discuss quarter forecast
medic devic organ fxn result led double-digit growth ep heart failur structur heart
diabet deliv strong global sale growth organ led continu adopt freestyl libr
system libr reach nearli billion annual sale million user estim sequenti revenu
growth unit state user today abbot continu benefit expand manufactur
capac new geographi improv insur coverag system rel low cost expect mani
tailwind continu specif libr enter cover live unit state plan
addit libr manufactur line top invest continu work payer
streamlin libr coverag less prerequisit believ abbott posit aggress target new
patient especi work new partner cgm integr smart pump pen softwar solut
despit impress growth last year believ abbott continu momentum given
larg under-penetrated core market opportun estim million global diabet patient countri
sell today manag also highlight initi traction patient outsid core market purchas libr
cash price given lack insur coverag demonstr potenti libr expand outsid core market
doubl current revenu run-rat time believ libr uniqu cost technolog posit
market posit well sever year strong growth given tailwind diabet monitor technolog relat
libr launch time unit state remain uncertain manag continu work fda normal
question believ libr approv necessari mani potenti futur pump partnership
structur heart sale grew organ strength led strong adopt util mitraclip
nearli million sale recent momentum encourag consid slightli delay
expect reimburs treatment secondari mr second quarter oppos first quarter
view indic strong market demand interest abbott mitraclip expect growth
support reimburs secondari mr expand potenti acceler growth well
earli contribut new product launch like triclip tricuspid valv clip tendyn mitral valv replac
approv portico tavr taken togeth believ mitraclip sustain structur heart growth
potenti acceler growth expand reimburs new product launch segment
neuromodul world-wide sale growth unit state partli offset growth
intern believ margin segment saw continu improv also believ continu face
challeng manag cite tough year driven salesforc expans disrupt earli year market
declin express salesforc disrupt pass new rep ramp product believ
market innov cycl improv thu market growth rate abbott launch new proclaim xr low-dos
recharge-fre system earli fourth quarter saw earli posit impact believ product along
pipelin includ mri indic new rf ablat gener potenti ad devic connect help
reinvigor growth segment proclaim xr data expect present upcom north american
neuromodul societi meet though believ devic primarili batteri play abl doubl tripl
batteri life non-recharg devic individu product smaller scale collect expect arm
rep competit offer model full year growth
diagnost organ fxn result segment follow similar trend saw
growth midsingle-digit rang compani guid surpris largest franchis led way
laboratori largest sub-seg post organ fxn growth directli line estim reflect
plan menu expans help fuel growth addit rapid diagnost aler show modest
beat model come organ fxn versu estim
overal focu remain compani abil continu grow lab roll-out alin system
still earli inning launch still expect sever new approv come later fuel growth
beyond well abil stabil turn around aler rapid diagnost new product
introduct refresh also continu growth infecti diseas test id platform cardio-
nutrit organ fxn sale growth led strength southeast asia latin america above-market
growth unit state result broad base across adult world-wide growth organ pediatr
world-wide growth organ segment strength quarter despit continu challeng china
though believ compani strategi place name steadi stream new product address competit
dynam abbott forecast growth full year first quarter
establish pharmaceut organ fxn result led key emerg market india brazil russia
china sale geographi increas organ basi exclud unfavor effect fx
believ busi continu execut brand gener strategi emerg market compani built
breadth depth omni-channel presenc therapi class abbott forecast mid- high-single-digit
growth first quarter full year
posit abbott cash balanc continu grow rais question around manag
deploy asset littl surpris manag continu state feel comfort capit posit strateg
flexibl net debt/ebitda roughli time compar time end time follow
close st jude acquisit earli look forward model leverag near time seem
level maxim capit structur compani opportun layer new product
compani fulli fund numer intern growth initi manufactur expans singl biggest
question stock type busi develop activ compani pursu
believ capit structur time make sens longer term whether compani new manag elect conduct
sever smaller one larg transact debat note comment much activ
near term said would stun someth come come month quarter
relat specif capit alloc commentari manag reiter focu increas payment
dividend decemb invest new product alin roll-out manufactur capac extens libr
mitraclip tact share repurchas announc billion share repurchas author septemb expect
use mainli off-set dilut continu debt paydown matur lastli still open acquisit
manag indic look deal right though would continu look asset meet
certain strateg opportunist threshold
guidanc organ sale growth rang support follow
establish pharmaceut mid- high-single-digit growth
 nutrit growth
 diagnost mid- high-single-digit growth
 medic devic double-digit growth similar
beyond top line adjust earn per share year expect rang
model reflect growth midpoint
first quarter specif manag expect segment growth
establish pharmaceut mid- high-single-digit growth
 nutrit growth
 diagnost mid- high-single-digit growth
 medic devic double-digit growth similar
adjust earn per share first quarter expect rang midpoint
sale slightli increas sale estim billion reflect organ growth
earn decreas adjust ep estim account small beat
fourth quarter off-set neg currenc headwind impli year-over-year growth
sale introduc sale estim billion reflect organ fxn growth
earn introduc adjust ep estim reflect growth
